CTVA vs AMGN vs BIIB vs GILD

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). Biogen Inc. (BIIB) offers the better valuation at 21. 4x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Corteva, Inc. (CTVA) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Biogen Inc.

(BIIB) is the cheapest at 21. 4x versus Gilead Sciences, Inc. at 351. 3x. On forward P/E, Biogen Inc. is actually cheaper at 13. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Corteva, Inc. wins at 1. 87x versus Amgen Inc. 's 5. 02x — a reasonable growth-adjusted valuation.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +123. 4%, compared to -30. 4% for Biogen Inc. (BIIB). Over 10 years, the gap is even starker: CTVA returned +195. 9% versus BIIB's -27. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Corteva, Inc.

(CTVA) is the lower-risk stock at 0. 29β versus Gilead Sciences, Inc. 's 0. 66β — meaning GILD is approximately 124% more volatile than CTVA relative to the S&P 500. On balance sheet safety, Corteva, Inc. (CTVA) carries a lower debt/equity ratio of 11% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -91. 6% for Gilead Sciences, Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus 1. 7% for Gilead Sciences, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 5. 8% for GILD. At the gross margin level — before operating expenses — GILD leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Corteva, Inc. (CTVA) is the more undervalued stock at a PEG of 1. 87x versus Amgen Inc. 's 5. 02x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Biogen Inc. (BIIB) trades at 13. 0x forward P/E versus 22. 3x for Corteva, Inc. — 9. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 21. 3% to $161. 88.

In this comparison, AMGN (2.

9% yield), GILD (2. 3% yield), CTVA (0. 8% yield) pay a dividend. BIIB does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Corteva, Inc.

(CTVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 8% yield, +195. 9% 10Y return). Both have compounded well over 10 years (CTVA: +195. 9%, BIIB: -27. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CTVA (Basic Materials) and AMGN (Healthcare) and BIIB (Healthcare) and GILD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

CTVA, AMGN, GILD pay a dividend while BIIB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.